Abbott’s Volt™ Pulsed Field Ablation System is the next generation of cardiac ablation technology built on a distinctive balloon-in-basket design to treat people with heart rhythm ...
Settlement does not represent any finding of fault or liability As the government has previously indicated, it has closed its criminal investigation on this matter Tests by government ...
Abbott's TactiFlex™ Duo Ablation Catheter, Sensor Enabled™ combines pulsed field ablation (PFA) and radiofrequency (RF) energy in a single catheter to treat complex atrial fibrillation (AFib) cases ...
ABBOTT PARK, Ill., Jan. 16, 2019 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that it has exercised its option to purchase Cephea Valve Technologies, Inc., a privately held medical device ...
The table above provides additional details regarding the specified items described on table titled "Non-GAAP Reconciliation of Financial Information." Reflects the net tax benefit associated with the ...
The table above provides additional details regarding the specified items described on table titled "Non-GAAP Reconciliation of Financial Information." Restructuring and cost reduction initiative ...
Libre Duo 10 Day is a first-of-its-kind, two-in-one biowearable that monitors glucose and helps detect rising ketone levels that can lead to diabetic ketoacidosis (DKA), a serious health condition for ...
-- More than 50% of people with diabetes who have been diagnosed with COVID-19 are hospitalized, according to a report from the Centers for Disease Control and Prevention (CDC)¹ -- FreeStyle Libre 14 ...
Abbott's Amplatzer Amulet Left Atrial Appendage Occluder device and related accessories were transferred from Structural Heart to Electrophysiology on January 1, 2026. As a result, $101 million of ...
Agreements will resolve the Gill case and claims involving approximately 2,000 other individuals Abbott and the medical community stand by the safety of preterm infant formulas Regulators and medical ...
Abbott Reports First-Quarter 2026 Results; Updates Guidance to Reflect Acquisition of Exact Sciences
*Beginning in 2026, Abbott aggregated its previously reported Rapid Diagnostics, Molecular Diagnostics, and Point of Care businesses into the Rapid and Molecular Diagnostics business. On March 23, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results